• QUANTRO to enable discovery of novel therapeutics that interfere with disease-causing transcriptional programs in cancer and other diseases.
• Transcriptional Fingerprinting to transform high-throughput drug discovery in cell-based compound screening.
• QUANTRO seed-financed by Boehringer Ingelheim Venture Fund and Evotec.
21.07.2020 | Full Press Release English Version
21.07.2020 | Full Press Release German Version
From left to right: J. Zuber, D. Nachtigall, S. Ameres | Photographer: L. Schedl